Hatem A Azim

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
  2. pmc Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 31:73-9. 2013
  3. doi Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies
    Hatem A Azim
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, 1000 Brussels, Belgium
    Cancer Treat Rev 38:834-42. 2012
  4. doi Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet and l Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Breast Cancer Res Treat 133:387-91. 2012
  5. ncbi Managing cancer during pregnancy: what evidence do we have?
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Pol Arch Med Wewn 121:29-34. 2011
  6. pmc Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis
    Hatem A Azim
    Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e62451. 2013
  7. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
  8. doi Prevention and management of major side effects of targeted agents in breast cancer
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Crit Rev Oncol Hematol 84:e79-85. 2012
  9. doi Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Eur J Cancer 47:74-83. 2011
  10. doi Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 18:1341-51. 2012

Detail Information

Publications14

  1. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
    ....
  2. pmc Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 31:73-9. 2013
    ..We questioned the impact of pregnancy on disease-free survival (DFS) in women with history of breast cancer (BC) according to estrogen receptor (ER) status...
  3. doi Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies
    Hatem A Azim
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, 1000 Brussels, Belgium
    Cancer Treat Rev 38:834-42. 2012
    ..Pregnancy-associated breast cancer (PABC) is relatively rare with considerable controversy regarding its prognosis...
  4. doi Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet and l Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Breast Cancer Res Treat 133:387-91. 2012
    ..We are currently initiating a collaboration to collect similar data from the other large adjuvant trastuzumab trials to confirm these findings...
  5. ncbi Managing cancer during pregnancy: what evidence do we have?
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Pol Arch Med Wewn 121:29-34. 2011
    ..In this review, we will consider the available evidence for managing pregnant women with cancer to provide some guidance for physicians dealing with these patients...
  6. pmc Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis
    Hatem A Azim
    Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e62451. 2013
    ..SPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast cancer (BC)...
  7. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
    ..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies...
  8. doi Prevention and management of major side effects of targeted agents in breast cancer
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Crit Rev Oncol Hematol 84:e79-85. 2012
    ..We critically analyse the available evidence and provide some insights on how to manage these toxicities in the clinical setting...
  9. doi Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Eur J Cancer 47:74-83. 2011
    ..Hence, we conducted a meta-analysis to understand the effect of pregnancy on overall survival of women with a history of breast cancer...
  10. doi Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 18:1341-51. 2012
    ..Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age...
  11. doi Motherhood after breast cancer: searching for la dolce vita
    Hatem A Azim
    Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 11:287-98. 2011
    ..In addition, we will discuss the different fertility-preservation techniques available for these patients...
  12. doi Rituximab in Hodgkin lymphoma: is the target always a hit?
    Kamal S Saini
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 37:385-90. 2011
    ..A systematic review of the literature is also presented...
  13. doi Clinical development of new formulations of cytotoxics in solid tumors
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 24:325-31. 2012
    ..To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy...
  14. doi Simultaneous targeting of estrogen receptor and HER2 in breast cancer
    Hatem A Azim
    Jules Bordet Institute, Department of Medical Oncology, Boulevard Waterloo, 121, 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 10:1255-63. 2010
    ..We analyze clinical evidence regarding the combined use of AIs and anti-HER2-targeted agents. We also touch on possible mechanisms of resistance and ways to improve research in this field...